Onconetix, Inc. (ONCO) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-13

How it makes money

It anticipates revenue from the Proclarix prostate cancer test in Europe and U.S. sales through a license agreement with LabCorp.

Profitability is centered on Proclarix, a protein-based blood test for men with Prostate-Specific Antigen (PSA) levels in the 20% to 40% diagnostic "grey zone." The company earns by helping physicians avoid negative or clinically insignificant biopsies, which currently account for over 50% of elevated PSA procedures.

While CE-marked and currently for sale in Europe, the primary path to U.S. revenue is a license agreement with LabCorp to market the diagnostic as a lab-developed test (LDT). Profits will be driven by clinical adoption and the ability to integrate into existing laboratory workflows using the enzyme-linked immunosorbent assay (ELISA) standard.

What protects it: the moat

It relies on the proprietary Proclarix Risk Score and the integration of its assays into existing ELISA-equipped laboratory workflows.

The company’s competitive advantage is management's claim of a proprietary Proclarix Risk Score that provides immediate diagnostic support for prostate cancer treatment decisions. This mechanism protects its market position by reducing the need for additional medical intervention or specialized laboratory equipment.

Because Proclarix assays utilize the standard ELISA format, local diagnostic laboratories can adopt the test without significant capital expenditure. This integration creates a barrier to entry for rivals who might require proprietary hardware, as laboratories prefer markers that fit their current high-volume processing capabilities.

What growth costs

It must fund commercial scale-up for Proclarix while managing a $9.7 million annual cash burn from operating activities.

The business structurally requires high reinvestment in product validation studies, intellectual property maintenance, and hiring specialized personnel to support its commercial launch. It spent $9.7 million in cash for operating activities during 2025 and reported a working capital deficit of $3.1 million.

Maintaining its public listing adds significant costs, particularly due to a mandatory Nasdaq Panel Monitor through July 2026. Management explicitly states that current cash balances are insufficient to fund operations for a full year, necessitating continuous reliance on Series D and E PIPE financings to survive.

What could damage it

Failure to satisfy the $12.5 million net cash condition for the Realbotix merger could lead to liquidation given current liabilities.

The company’s survival depends on a complex share exchange with Realbotix. If the business cannot maintain at least $12.5 million in net cash at closing, the transaction may fail, potentially triggering $500,000 in termination fees plus expenses.

With $9.1 million in total current liabilities and only $5.2 million in cash as of year-end 2025, a failed merger or an inability to raise more capital would likely result in bankruptcy. In such a scenario, creditors would have priority over stockholders, who would receive nothing.

About Onconetix, Inc.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Other companies in Biotechnology